- Home
- USEG vs XGN Comparison
USEG vs XGN Comparison
Compare USEG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEG
- XGN
- Stock Information
- Founded
- USEG 1966
- XGN 2002
- Country
- USEG United States
- XGN United States
- Employees
- USEG N/A
- XGN N/A
- Industry
- USEG Oil & Gas Production
- XGN Medical Specialities
- Sector
- USEG Energy
- XGN Health Care
- Exchange
- USEG Nasdaq
- XGN Nasdaq
- Market Cap
- USEG 39.8M
- XGN 44.7M
- IPO Year
- USEG N/A
- XGN 2019
- Fundamental
- Price
- USEG $1.67
- XGN $2.98
- Analyst Decision
- USEG Strong Buy
- XGN Buy
- Analyst Count
- USEG 2
- XGN 1
- Target Price
- USEG $2.00
- XGN $7.00
- AVG Volume (30 Days)
- USEG 100.1K
- XGN 21.5K
- Earning Date
- USEG 11-12-2024
- XGN 11-12-2024
- Dividend Yield
- USEG N/A
- XGN N/A
- EPS Growth
- USEG N/A
- XGN N/A
- EPS
- USEG N/A
- XGN N/A
- Revenue
- USEG $21,611,000.00
- XGN $55,751,000.00
- Revenue This Year
- USEG N/A
- XGN $9.98
- Revenue Next Year
- USEG $8.50
- XGN $13.63
- P/E Ratio
- USEG N/A
- XGN N/A
- Revenue Growth
- USEG N/A
- XGN 8.00
- 52 Week Low
- USEG $0.81
- XGN $1.30
- 52 Week High
- USEG $1.73
- XGN $3.71
- Technical
- Relative Strength Index (RSI)
- USEG 66.68
- XGN 58.94
- Support Level
- USEG $1.36
- XGN $2.62
- Resistance Level
- USEG $1.45
- XGN $2.97
- Average True Range (ATR)
- USEG 0.10
- XGN 0.21
- MACD
- USEG 0.01
- XGN 0.05
- Stochastic Oscillator
- USEG 85.71
- XGN 83.33
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business activities in South Texas and the Williston Basin in North Dakota. The company generates revenue from its interest in the sales of oil and natural gas production.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.